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Abstract 
The focus of this paper is on quantifying the capacity of covariates in devising efficient 
treatment rules when data from a randomized trial are available. Conventional one-
variable-at-a-time subgroup analysis based on statistical hypothesis testing of covariate-
by-treatment interaction is ill-suited for this purpose. The application of decision theory 
results in treatment rules that compare the expected benefit of treatment given the 
patient’s covariates against a treatment threshold. However, determining treatment 
threshold is often context-specific, and any given threshold might seem arbitrary at the 
reporting stages of a clinical trial. We propose a threshold-free metric that quantifies 
the capacity of a set of covariates towards finding individuals who will benefit the most 
from treatment. The construct of the proposed metric is comparing the expected 
outcomes with and without knowledge of covariates when one of a two randomly 
selected patients are to be treated. We show that the resulting index can also be 
expressed in terms of integrated treatment benefit as a function of covariates over the 
entire range of treatment thresholds. We also propose a semi-parametric estimation 
method suitable for out-of-sample validation and adjustment for optimism. We use data 
from a clinical trial of preventive antibiotic therapy for reducing exacerbation rate in 
Chronic Obstructive Pulmonary Disease to demonstrate the calculations in a step-by-
step fashion. The proposed index has intuitive and theoretically sound interpretation 
and can be estimated with relative ease for a wide class of regression models. Beyond 
the conceptual developments presented in this work, various aspects of estimation and 
inference for such metrics need to be pursued in future research. 
 
Keywords: Subgroup Analysis; Prediction Modeling; Clinical Trials; Regression Analysis 
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Introduction 
Clinical trials are major undertakings to evaluate the merits of medical interventions and 
are gateways to their market entry. Besides estimating average treatment effect, 
evaluating heterogeneity of treatment effect across identifiable subgroups is a common 
practice in the reporting stage of trials: 61% of all trials published during one year in a 
major medical journal reported on at least one such subgroup analysis(1). In addition to 
providing insight into the underlying disease processes, subgroup analysis can provide 
evidence as to whether the treatment should be provided to a subset of patients who 
will benefit the most from it(2).  
 
The classical approach towards subgroup analysis in clinical trials is through statistical 
significance testing for the presence of covariate-by-treatment interaction(3). The 
problems with this approach are well recognized and extensively discussed(4). In brief, 
one issue is that type I and II error rates are not strictly under the control of the 
investigator for exploratory subgroup analysis. Another is that statistical testing of one 
covariate at a time makes it difficult to compare the benefit of treatment between two 
individuals as they likely differ in several aspects. Moreover, neither the level of 
statistical significance, nor the magnitude of the coefficient for the interaction term, the 
latter being dependent on the scale of the covariate, can be used to compare covariates 
in terms of their relative contribution towards treatment effect heterogeneity. Further, 
the presence of interaction on the ‘scale of estimation’ for subgroup analysis (often a 
relative scale) does not mean its presence on the ‘scale of interest’ for decision-making 
(often the absolute scale), or vice versa(2).  
 
In light of these issues, there has been a call towards a ‘risk-based’ approach for 
subgroup analysis(4). In such an approach, covariates are combined into a single 
(externally or internally developed) risk score(4). The predicted risk score is then 
treated as the subgroup-defining variable. More recently, direct estimation of treatment 
benefit, the difference in the outcome with and without treatment as a function of the 
covariates of interest, is proposed(2,5). VanderWeele et al explored how covariates can 
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be used to formulate optimal treatment rules when data on treatment assignment, 
covariates, and treatment outcomes are available(5). They examined a variety of 
objective functions and showed that they all result in applying a threshold on the 
expected difference in outcomes with and without the treatment given the patient’s 
observed characteristics.  
 
While such a move towards theoretically sound subgroup analysis is appealing, the 
practicality of a full decision-theoretic approach in clinical trials can be questioned. 
Maximizing commonly defined decision-theoretic objective functions requires weighting 
the short- and long-term outcomes of alternative treatment decisions. This requires a 
deep contextual investigation which can be difficult especially for new interventions. 
Reporting on the weighting mechanism might be seen as a distraction from the main 
findings of the clinical trial.  
 
We are motivated by the approach taken by the marker development community facing 
a similar problem. Often, biomarkers and clinical prediction models need to be coupled 
with a positivity rule to enable binary classifications, such as labelling an individual as 
diseased versus healthy. Classical findings from decision theory identify the optimal 
positivity rule based on the consequences of test results(6,7). However, it is argued 
that in the early stages of marker development, applying such decision rules to find the 
optimal threshold can be challenging or even off-putting(8). Instead, the interest is 
focused on threshold-free, ‘global’, measures of discriminatory capacity of the marker, 
such as the Area Under the Curve (AUC) of the Receiver Operating Characteristic curve 
and the closely related Concordance (C) statistic, or the Integrated Discrimination 
Improvement index(9). The implicit promise is that if a marker performs well (or better 
than another marker) on these metrics, it is likely to have some value (or more value 
compared to another marker) when a specific threshold is applied.  
 
In our opinion, subgroup analysis for clinical trials should similarly remain detached 
from the potentially contentious weighting of the outcomes. While a full decision-
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theoretic approach can take place in its due course, trialists can focus on ‘AUC-like’ 
metrics that quantify the overall capacity of covariates towards concentrating treatment 
benefit. In this work we propose such an index. Our proposed index is relatively easy to 
calculate, has intuitive interpretation, and does not suffer from many of the issues that 
hamper interpretations based on statistical significance of interaction terms. Our focus 
in this paper is on the conceptual foundations, and we relegate important issues 
regarding the merits of model selection, variable selection, estimation, and validation 
methods to future developments. 
 
Notation and context 
We focus on randomized trials comparing two interventions among 𝑛 individuals. By 𝐴 
we define the treatment variable, with 𝐴 = 1 indicating treatment and 𝐴 = 0 indicating 
no treatment. By 𝐗 we refer to the set of covariates of interest for subgroup analysis. 
We define 𝑌0 and 𝑌1 as the (possibly counterfactual) outcomes for each patient under 
no treatment and treatment, respectively. The observed outcome, denoted by 𝑌, is 
(1 − 𝐴). 𝑌0 + 𝐴. 𝑌1. We assume that observation on one unit is unaffected by the 
particular assignment of treatments to the other units(10). Our objective is to devise a 
metric that quantifies how 𝐗 can help us find individuals with the highest expected 
treatment benefit on the decision scale, which we define to be 𝑏 = 𝐸(𝑌1 − 𝑌0) if the 
outcome is favorable (e.g., 5-year survival) or 𝑏 = 𝐸(𝑌0 − 𝑌1) if the outcome is 
unfavorable (e.g., disease recurrence). Without loss of generality, in what follows we 
assume that the outcome is an unfavorable event and treatment labels are such that 
the population-average treatment benefit is positive.  
 
Our derivations start by estimating the expected benefit of treatment as a function of 
covariates. In most cases, this function is based on a parametric ‘risk model’ that 
estimates 𝐸(𝑌|𝐗, 𝐴), the rate or risk of the outcome as a function of covariates and 
treatment. The expected treatment benefit for the ith subject can then be estimated as 
 
?̂?𝑖 = ?̂?(𝑌𝑖|𝐗𝑖, 𝐴𝑖 = 0) − ?̂?(𝑌𝑖|𝐗𝑖, 𝐴𝑖 = 1). 
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The coefficients of such a regression model can be fitted through maximum likelihood 
(ML) estimation. However, our objective is not to examine the causal relation between 
covariates and outcomes; rather, the interest is to investigate the performance of 
covariate(s) in predicting treatment outcomes in future patients. In this context, severe 
biases can arise when the same dataset is used for both ML parameter estimation and 
evaluation of the predictive performance of the model(11). It is known that 
regularization techniques, such as shrinking the parameter estimates towards the null, 
can improve the predictive performance in a new sample(12,13). The use of ensemble 
methods (such as the super-learner(14)) can also be considered, but the nuances of 
feature selection and estimation is not the primary focus of this work. 
 
To what extent covariates can help formulate an efficient treatment rule? 
If a universal treatment decision (treating all or treating none) will be applied to the 
population, the knowledge of patient covariates will be irrelevant. Such knowledge 
matters only if the treatment decision is moved from the population level to the 
individual level. To quantify the value of such knowledge, we contrast the outcomes of 
population-level versus individual-level treatment decisions through an abstract 
comparison that has a broad analogy with the concept behind the C statistic.  
 
Imagine the task is front of us is to give treatment to one, and only to one, subject 
among a randomly selected pair of subjects. We compare the efficiency of this task with 
and without knowing about covariates. When we have knowledge of covariates, the 
most efficient treatment rule is the one that provides treatment to the subject with 
higher expected treatment benefit (or at random if the estimates are tied) given the 
value of covariates. The average benefit of such a covariate-informed rule (compared 
with not treating any of the two subjects) will therefore be 𝐸{𝑚𝑎𝑥(𝐵1, 𝐵2)}, where 𝐵1 
and 𝐵2 are random draws from the distribution of 𝑏. On the other hand, without 
knowledge of covariates, no rule is any more (or less) efficient than random treatment 
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assignment between the two subjects. The average benefit of such a covariate-agnostic 
treatment rule is 𝐸(𝐵), where 𝐵 is a random draw from the distribution of 𝑏. The more 
heterogeneous the distribution of 𝑏, the more disparate the results of such covariate-
informed and covariate-agnostic decisions will be. This is the basis of our proposed 
metric. 
 
Concentration of benefit index (𝑪𝒃)  
We start by focusing on the difference between the covariate-informed and covariate-
agnostic treatment rules:  
 
𝛥𝑏 = 𝐸{𝑚𝑎𝑥(𝐵1, 𝐵2)} − 𝐸(𝐵) =
1
2
. 𝐸(|𝐵1 − 𝐵2|). 
 
𝛥𝑏 is a threshold-free quantity that can be estimated for any outcome and arbitrary set 
of covariates. Its possible values range between 0 and +∞. It has a value of 0 when 
𝑣𝑎𝑟(𝐵) = 0, indicating that there is no gain in individualizing treatment decisions. 
Generally, the more dispersed the distribution of 𝑏, the larger the value of 𝛥𝑏.  
 
While 𝛥𝑏 is a threshold-free metric, it is still context-specific as it is in the same unit as 
the benefit of treatment. One approach towards developing a dimensionless metric is to 
focus on 𝛥𝑏/𝐸(𝐵). This quantity is equal the Gini index for benefit (for a random 
variable 𝑋, 𝐺𝑖𝑛𝑖𝑋 =
𝐸(|𝑋1−𝑋2|)
2.𝐸(𝑋3)
 where 𝑋1, 𝑋2, and 𝑋3 are independent random draws from 
the distribution(15)). While the Gini index for strictly non-negative quantities such as 
risk is well known and is well behaved (e.g., always bounded in [0,1])(16), this is not 
necessarily the case with treatment benefit. Our main concern is that this quantity can 
grow without bounds if 𝐸(𝐵) is close to zero, resulting in large values that are difficult 
to interpret.  
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Instead, our proposed index is a dimensionless metric obtained through dividing 𝛥𝑏 by 
𝐸{𝑚𝑎𝑥(𝐵1, 𝐵2)} , the larger quantity of the two terms comprising 𝛥𝑏. We call the 
resulting quantity the ‘Concentration of Benefit’ index (𝐶𝑏): 
𝐶𝑏 = 1 −
𝐸(𝐵)
𝐸{𝑚𝑎𝑥(𝐵1, 𝐵2)}
=
𝐺𝑖𝑛𝑖𝑏
1 + 𝐺𝑖𝑛𝑖𝑏
. 
 
𝐶𝑏 ranges between (0,1) and can be expressed in percentages: a 𝐶𝑏 of p% means that 
the covariate-agnostic treatment rule is (100-p)% as efficient as the covariate-informed 
one in the two-subject experiment explained above. When 𝑣𝑎𝑟(𝐵) = 0, there is no extra 
benefit in individualized versus population-based treatment, and 𝐶𝑏 = 0. If the expected 
treatment benefit for every individual is non-negative, given that 𝐸{max(𝐵1, 𝐵2)} ≤
2. 𝐸(𝐵), 𝐶𝑏 will be bounded in [0, 0.5]. If there is ‘qualitative’ interaction such that the 
expected treatment benefit is positive in some subjects and negative in others, 𝐶𝑏 can 
be more than 0.5. At extreme, 𝐶𝑏 = 1, indicating that there is no benefit in population-
based treatment, but individualized treatment can be beneficial. For example, if the 
population consists of equal proportion of males and females, and the expected 
treatment benefit is +a in females and –a in females, 𝐸(𝐵) = 0 and 𝐶𝑏 = 1 (and 
𝐺𝑖𝑛𝑖𝑏 = +∞). 
 
Relationship with treatment threshold 
While the concept of giving treatment to one in a pair might seem abstract, it has a firm 
relationship with treatment rules based on treatment thresholds, such as those explored 
by VanderWeele et al(5). Imagine we would like to compare the performance of 
covariate-informed and covariate-agnostic treatment rules when a fraction 𝑝 of the 
population would receive the treatment. For the covariate-informed scenario, the most 
efficient strategy is to provide the treatment to the proportion 𝑝 of the population with 
the highest values of 𝑏. Let 𝐹−1 be the quantile function of 𝑏 in the population; this 
strategy entails setting a treatment threshold at 𝐹−1(1 − 𝑝) on 𝑏, such that only 
subjects with higher expected treatment benefit shall receive the treatment. The 
population benefit of such a strategy will be  
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𝑏𝑒𝑛𝑒𝑓𝑖𝑡(𝑝) = 𝑝. 𝐸(𝐵|𝐵 > 𝐹−1(1 − 𝑝)) = ∫ 𝐹−1(𝑞)
1
1−𝑝
. 𝑑𝑞. 
 
Because we might not know the treatment threshold, we can assume that it can result 
in any proportion of the population, with equal likelihood, to be treated 
(𝑝~𝑢𝑛𝑖𝑓𝑜𝑟𝑚(0,1)). As such, the expected (integrated) treatment benefit across the 
entire range of thresholds is  
 
𝐸{𝑏𝑒𝑛𝑒𝑓𝑖𝑡(𝑝)} = ∫ [∫ 𝐹−1(𝑞). 𝑑𝑞
1
1−𝑝
] . 𝑑𝑝 =
1
0
1
2
. 𝐸{𝑚𝑎𝑥(𝐵1, 𝐵2)}. 
 
 
On the other hand, in the absence of any information on treatment benefit, the 
covariate-agnostic rule can do no better (or worse) than randomly assigning a 
proportion 𝑝 to treatment, with population benefit of 𝑏𝑒𝑛𝑒𝑓𝑖𝑡(𝑝) = 𝑝. 𝐸(𝐵). The 
integrated benefit of treatment for the covariate-agnostic rule across all 𝑝 is therefore 
1
2
𝐸(𝐵). Given these equalities, 1 − 𝐶𝑏 is the average efficiency of covariate-agnostic 
versus covariate-informed treatment rule across the entire range of treatment 
thresholds. 
 
Estimation 
For a trial of size 𝑛, we define ?̂? = {?̂?1 ≥ ?̂?2 ≥ ?̂?3, . . . , ?̂?𝑛} as the ordered, from large to 
small, vector of estimated treatment benefits. Here we propose two classes of 
estimators for 𝐶𝑏. 
 
Parametric (model-based) estimator 
One approach is to directly work with the model-based estimates of expected treatment 
benefits for each subject. Indeed, ?̂?(𝐵) =
1
𝑛
. ∑ ?̂?𝑖
𝑛
𝑖=1 . For 𝐸{max(𝐵1, 𝐵2)}, given that in 
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the ordered vector ?̂?, ∀𝑖 ≤ 𝑗, max(?̂?𝑖, ?̂?𝑗) = ?̂?𝑖, instead of averaging across all pairs in the 
sample, we can proceed as  
?̂?{𝑚𝑎𝑥(𝐵1, 𝐵2)} = 2{
1
𝑛2
. ∑ ?̂?(𝑖)
𝑛
𝑖=1
−
1
𝑛
. ?̂?(𝐵)}, 
 
where ?̂?(𝑘) = ∑ ?̂?𝑖
𝑘
𝑖=1   is the partial sum of ?̂? up to and including its k
th element.  
 
This purely model-based approach for estimating 𝐶𝑏 cannot be used for evaluating the 
out-of-sample performance of the model. Imagine the prediction model for expected 
treatment benefit in the original sample is to be evaluated in a new clinical trial data. 
The prediction model can be used to estimate ?̂?𝑖 for each new subject based on their 
observed covariates, and therefore allows estimating 𝐶𝑏; but such an approach is 
independent of the observed outcomes in the new sample. This limits evaluating the 
external validity of estimates and investigation of the level of optimism of the estimand. 
 
Semi-parametric estimator 
Here we propose an alternative semi-parametric estimation method that is influenced 
by the actual outcomes in the new sample. Our derivations closely follows that of Zhao 
et al(17). We note that a consistent estimator for 𝐸(𝐵) in the new sample with random 
treatment assignment is the difference in the mean of observed outcomes between the 
two groups. For example, for a binary outcome in the absence of censoring,  
?̂?(𝐵) =
∑ 𝐼(𝐴𝑖 = 0). 𝑌𝑖
𝑛
𝑖=1
∑ 𝐼(𝐴𝑖 = 0)
𝑛
𝑖=1
−
∑ 𝐼(𝐴𝑖 = 1). 𝑌𝑖
𝑛
𝑖=1
∑ 𝐼(𝐴𝑖 = 1)
𝑛
𝑖=1
. 
 
Similarly, for 𝐸{𝑚𝑎𝑥 (𝐵1, 𝐵2)}, we can replace the estimate of the partial sum of 
expected treatment benefits up to the kth subject in the equation for parametric 
estimator with the observed difference in the outcomes between the two arms among 
the first k subjects with the highest predicted treatment benefit:  
?̂?(𝑘) = 𝑘.
∑ 𝐼(𝐴𝑖 = 0). 𝑌𝑖
𝑘
𝑖=1
∑ 𝐼(𝐴𝑖 = 0)
𝑘
𝑖=1
− 𝑘.
∑ 𝐼(𝐴𝑖 = 1). 𝑌𝑖
𝑘
𝑖=1
∑ 𝐼(𝐴𝑖 = 1)
𝑘
𝑖=1
. 
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We note that for the first few values of k, the estimator might result in undefined 
values. For example, for k=1 (the first subject), either 𝐴1 = 0 or 𝐴1 = 1, and the other 
term is 0/0. In the implementation of this estimator, we have carried backward the first 
defined value within each treatment group. The practical impact of different approaches 
to overcome this issue should only be of concern in small samples. 
 
We consider this method semi-parametric as it is still based on a (parametric) model for 
𝐸(𝑌|𝐗, 𝐴), but the model acts as a ranking mechanism for observations, and the 
estimate of cumulative benefit is obtained non-parametrically from the ranked vector of 
observed outcomes.  
 
Quantifying uncertainty 
Like any summary statistic estimated form a finite sample, 𝐶𝑏 has a sampling 
distribution. The interpretation of 𝐶𝑏 as the relative performance of individualized versus 
population-based treatment across all treatment thresholds provides a decision-
theoretic perspective which makes inference less relevant(18). However, the end-user 
might still be interested in examining the range of values that are compatible with the 
data. Closed-form equations might exist for variance functions assuming certain 
parametric distribution for 𝑏. However, it is important to incorporate uncertainty in the 
model structure. For constructing confidence intervals for the general case, we suggest 
a bootstrapping approach in which all the calculations (including the estimation of the 
shrinkage penalty term) are repeated within bootstrapped samples.  
 
Application: a clinical trial of preventive antibiotic therapy for Chronic 
Obstructive Pulmonary Disease (COPD) exacerbations 
COPD is a chronic airways disease characterized by the loss of lung function and chronic 
symptoms such as cough and shortness of breath. Exacerbations of COPD are periods 
of intensified disease activity and are associated with high risk of morbidity and 
mortality and increased use of healthcare resources(19). The MACRO study was a 
Version 2019.08.22  
13 
 
randomized trial of daily azithromycin, a broad-spectrum antibiotic, for the prevention 
of acute exacerbations of COPD(20). In this study, patients were randomized to either 
azithromycin (n=570) or placebo (n=572) and were followed for up to one year. The 
rate of exacerbations was 1.48 per patient-year in the azithromycin group, as compared 
with 1.83 in the placebo group (p=0.01). A proportional hazards model for the time to 
the first exacerbation demonstrated a 27% reduction in the rate of exacerbations in the 
azithromycin relative to the placebo group(20). However, using azithromycin will incur 
costs, and there are concerns around azithromycin therapy including the risk of adverse 
cardiovascular events(21). Targeting the subset of the COPD patients who will likely 
gain the most benefit from this therapy can be a more efficient strategy than treating 
all patients.  
 
In this context, a natural definition of benefit is the number of exacerbations avoided 
due to treatment over one unit of time, which we define to be one year. For the 
purpose of this example we focus on moderate (requiring outpatient care) and severe 
(requiring inpatient care) exacerbations. Mild exacerbations for which the patient will 
not use healthcare resources were not deemed relevant for preventive therapy. 
Because reduction in the absolute number of exacerbations is the outcome of interest, 
instead of the non-parametric proportional hazards model in the main analysis, we 
switch to a parametric count model of the outcome that considers all events during 
follow-up.  
 
As the subgroup-defining variables we focus on the following six covariates: sex, age at 
baseline, whether the patient was hospitalized due to a COPD exacerbation in the 12-
month period before enrollment, whether the patient received systemic corticosteroids 
due to a COPD exacerbation in the 12-month period before enrollment, forced 
expiratory volume at one second (FEV1 – a measure of lung function) at baseline, as 
well as the baseline St. George Respiratory Questionnaire (SGRQ) score (a measure of 
functional capacity, with higher scores indicating lower capacity). These variables were 
selected a priori by an expert clinician as potential predictors of exacerbation rate or 
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modifiers of treatment effect, which can conceivably be used to formulate a prediction 
score for benefit of preventive therapy. There were 1,108 patients with non-missing 
covariates, comprising the sample for this analysis. These patients were followed for an 
average of 0.94 years and contributed 544 events. As in the original analysis, we 
consider loss-to-follow-up to have occurred at random. A previous analysis 
demonstrated that the pattern of exacerbation occurrence was consistent with a 
constant hazard over time(22). Fewer than 4% of individuals died and a previous 
analysis showed little impact from the competing risk of death on the statistical 
inference on exacerbation rate(22). As the treatment is randomized, there is no 
structural confounding. The possibility of chance confounding (noticeable imbalance of 
covariates due to randomization(23)) was ruled out in an exploratory analysis (the 
standardized mean difference between treatment groups was less than 5% for all 
covariates). As such, we fitted a generalized linear model with negative binomial 
distribution and logarithmic link function to model the expected exacerbation rate as a 
function of treatment and covariates. We start by a ‘full’ model that includes both 
independent effects for 𝐴 and 𝐗, and their interaction for each of the 𝑚 covariates: 
 
?̂?(𝑌𝑖|𝐴𝑖 , 𝐗𝑖, 𝑇𝑖) = exp (𝛽0 + 𝛽𝑎. 𝐴𝑖 + ∑ 𝛽𝑗 . 𝑋𝑖,𝑗
𝑚
𝑗=1
+ ∑ 𝛽𝑎.𝑗. 𝐴𝑖 . 𝑋𝑖,𝑗
𝑚
𝑗=1
+ ln (𝑇𝑖)). 
 
Here, 𝐗 = {𝑋𝑖,𝑗: 𝑖 = 1,2, … , 𝑛; 𝑗 = 1,2, … , 𝑚} is vector of 𝑚 = 6 covariates for the i
th 
subject, 𝑌𝑖 is the number of exacerbations during follow-up, 𝐴𝑖 indicates treatment 
(1:daily azithromycin, 0:placebo), and 𝑇𝑖 is the follow-up time in years, whose logarithm 
enters the model as the offset variable.  
 
To estimate the parameters of this model, we chose the ridge regression in the main 
analysis, and unconstrained ML in a secondary analysis. Ridge applies an ℓ2 norm 
penalty of 𝜆. ∑ 𝛽2 to the likelihood function (when all independent variables are 
standardized) to prevent optimistic predictions(24). We used 10-fold cross-validation to 
find the optimal value of 𝜆 that minimized the mean-squared error of off-sample 
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predictions. All calculations were performed in R(25); we used the implementation of 
ridge regression provided in the glmnet package(26). We note that other popular 
regularization techniques, such as the least absolute shrinkage and selection operator 
(Lasso) can also be used(27). Lasso applies an ℓ1 norm penalty with the property that 
some coefficients can be shrunk to exactly zero, producing parsimonious prediction 
models; however, this feature of Lasso is less relevant to the present context, where 
the emphasis is on global predictive performance of covariates rather than publicizing 
any treatment rule.  
Table 1 provides the estimates of regression coefficients for both ridge and ML models, 
after all variables were standardized to have zero mean and unit variance. Using the 
ridge regression resulted in the shrinkage of the majority of variables towards zero.  
Table 1: Regression coefficients for the ridge and maximum likelihood estimates 
Variables Ridge regression 
estimates 
  
Unconstrained ML 
estimates  
Intercept -1.367 -1.959 
Main effects 
Treatment (1:azithromycin, 
0:placebo) -0.116 0.693 
Sex (female v. male) -0.155 -0.241 
Age (in years) -0.008 -0.004 
History of previous 
hospitalization due to 
COPD  
(binary) 0.744 0.976 
History of previous use of 
systemic corticosteroids  
(binary) 0.420 0.479 
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Baseline forced expiratory 
volume at one second 
(FEV1) -0.108 -0.176 
SGRQ score* 1.395 1.792 
Treatment by covariate interaction effects 
Sex  0.017 0.109 
Age  -0.003 -0.014 
History of previous 
hospitalization due to 
COPD  0.172 0.045 
History of previous use of 
systemic corticosteroids 0.005 0.121 
Baseline FEV1 -0.063 0.006 
SGRQ score* -0.118 -0.555 
*All variables are scaled to have zero mean and unit variance 
 
ML: ; maximum likelihood; COPD: Chronic Obstructive Pulmonary Disease; FEV1: 
forced expiratory volume at one second; SGRQ: St. George’s Respiratory 
Questionnaire  
 
Figure 1 demonstrates the histogram of estimated expected treatment benefits (?̂?) for 
each subject based on the reference model. On average, one year of treatment with 
azithromycin prevented 0.153 exacerbations. However, there was a marked variability 
in this number across the sample, with the interquartile range being 0.108 – 0.187.  
 
Figure 1: histogram of expected treatment benefit as a function of baseline covariates 
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For both ridge and ML models, we evaluate the parametric and semi-parametric 
estimations of 𝐶𝑏. Inference was based on 1,000 bootstraps, with parameter estimation 
and shrinkage being repeated within each bootstrapped sample.  
 
Note that the presence of variable follow-up times requires the incorporation of time in 
the semi-parametric estimators. For ?̂?(𝐵), the estimate is the difference in the annual 
exacerbation rate between the two groups. Similarly, for ?̂?{𝑚𝑎𝑥(𝐵1, 𝐵2)}, the partial 
sum component would be 
 
?̂?(𝑘) = 𝑘.
∑ 𝐼(𝐴𝑖 = 0). 𝑌𝑖
𝑘
𝑖=1
∑ 𝐼(𝐴𝑖 = 0)
𝑘
𝑖=1 . 𝑇𝑖
− 𝑘.
∑ 𝐼(𝐴𝑖 = 1). 𝑌𝑖
𝑘
𝑖=1
∑ 𝐼(𝐴𝑖 = 1)
𝑘
𝑖=1 . 𝑇𝑖
. 
 
The performance of the parametric versus semi-parametric estimators of 𝑆(. ) fcan be 
evaluated visually, as in Figure 2. 
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Figure 2: Running partial sum of model-estimated 𝑏 (continuous line) and its semi-
parametric estimator (jagged line) for the ridge regression.  
 
 
 
The parametric estimate of 𝐶𝑏 based on the ridge regression model was 0.171 (95%CI 
0.151 – 0.587), indicating that the population-level treatment is 82.9% as efficient as 
covariate-informed treatment on average across all treatment thresholds. The ML-based 
model yielded a value of 0.307 (95%CI 0.251 – 0.640). The semiparametric estimation 
yielded values of 0.249 (95%CI 0.137 – 0.761) for the ridge model and 0.275 (95%CI 
0.187 – 0.701) for the ML model.  
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A brief simulation study 
To evaluate the behavior of the proposed indices, a series of simulations were 
conducted. The empirical joint distribution of the six covariates from the case study was 
taken as their population distribution to generate a super-population of 10^7 simulated 
individuals. We modeled the true treatment effect under three scenarios: 1) strong 
interaction on the log scale, in which the ML estimates of the regression (Table 1) were 
used to generate simulated treatment outcomes; 2) weak interaction on the log scale, 
in which the ridge estimates (Table 1) were used; and 3) a null model, in which 
treatment effect was modeled not to be affected by any of the covariates. The 
population values of 𝐶𝑏 were as follows: 0.334 for the strong interaction scenario, 0.183 
for the weak interaction scenario, and 0 for the null scenario. 
 
For each scenario, we generated simulated clinical trials of small (n=400), medial 
(n=1,000), and large (n=5,000) sample sizes. Treatment was assigned to each subject 
at random with a probability of 0.5. Within each simulation loop, we fitted the penalized 
and unconstrained ML models (with the same structure as in the case study). Optimism 
adjustment was based on 200 bootstraps. A new model was fitted (including shrinkage 
estimation) in the bootstrapped sample (within-sample estimate), and was used to 
calculate the indices in the original sample (out-of-sample estimate). The difference 
between within-sample and out-of-sample estimates was averaged over bootstrap 
iterations. Results, based on 1,000 simulations, are provided in Table 3.  
 
Table 3: Results of the simulations  
 
 
N 
Parametric  Semi-parametric Semi-parametric,  
optimism adjusted 
Ridge ML Ridge ML Ridge ML 
Bias SD RMSE Bias SD RMSE Bias SD RMSE Bias SD RMSE Bias SD RMSE Bias SD RMSE 
 Strong interaction on the log scale  
(see Table 1 for regression coefficients for treatment effect; 𝐶𝑏 = 0.334) 
400 -0.018 0.130 0.131 0.120 0.132 0.178 0.086 0.168 0.189 0.122 0.161 0.202 -0.034 0.204 0.207 0.000 0.207 0.207 
1,000 -0.047 0.065 0.081 0.051 0.072 0.088 0.032 0.091 0.096 0.051 0.091 0.104 -0.051 0.103 0.115 -0.035 0.106 0.112 
5,000 -0.063 0.024 0.068 0.012 0.031 0.034 -0.001 0.039 0.039 0.014 0.038 0.041 -0.019 0.04 0.045 -0.008 0.04 0.041 
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Weak interaction on the log scale  
(see Table 1 for regression coefficients for treatment effect; 𝐶𝑏 = 0.183) 
400 0.095 0.146 0.174 0.249 0.143 0.287 0.196 0.183 0.268 0.246 0.171 0.299 0.053 0.215 0.221 0.086 0.222 0.238 
1,000 0.046 0.080 0.092 0.142 0.09 0.167 0.109 0.114 0.157 0.139 0.108 0.176 -0.011 0.124 0.124 0.001 0.127 0.126 
5,000 0.006 0.029 0.03 0.039 0.041 0.056 0.03 0.051 0.059 0.039 0.049 0.062 -0.019 0.061 0.064 -0.022 0.062 0.066 
Null model 
(No heterogeneity of treatment effect; 𝐶𝑏 = 0) 
400 0.102 0.067 0.122 0.396 0.133 0.418 0.230 0.186 0.296 0.394 0.136 0.417 0.133 0.187 0.229 0.221 0.186 0.289 
1,000 0.085 0.036 0.092 0.284 0.092 0.299 0.146 0.120 0.189 0.282 0.094 0.297 0.068 0.098 0.119 0.133 0.105 0.169 
5,000 0.073 0.02 0.076 0.149 0.041 0.155 0.072 0.060 0.094 0.148 0.043 0.154 0.033 0.045 0.056 0.064 0.050 0.081 
All simulations are run for 1,000 times. 
ML: maximum likelihood; SD: standard deviation; RMSE: Root mean square error 
 
Overall, ?̂?𝑏 generally behaved as expected for a consistent estimator, shrinking in bias, 
SD, and RMSE with larger sample sizes. The parametric ML estimator was upwardly 
biased, which could be severe in small sample sizes. Penalized regression moderately 
underestimated 𝐶𝑏 in the strong interaction scenario and overestimated it in the weak 
interaction scenario. Generally, penalized regression had lower dispersion (SD) than its 
ML counterpart, while semi-parametric estimators had generally higher dispersion than 
parametric ones. In the presence of covariate-by-treatment interaction, optimism 
adjustment generally removed the bias but increased the SD. There was no discernible 
difference between the ridge and ML estimators in both strong and weak interaction 
scenarios after optimism correction. Given that 𝐶𝑏 has its minimum population value 
under the null scenario (when outcome is not a function of covariates), it is expected 
that estimates would be upwardly biased. For the ML estimators, this bias persisted 
even with large sample sizes. Overall, judging by the root mean square error, the 
parametric model with shrinkage estimation prevailed in seven of the nine scenarios 
(with the two exceptions being parametric ML estimator without shrinkage for the 
strong interaction scenario, and optimism-adjusted semi-parametric ridge in the null 
scenario, outperforming it, both when N=5,000). 
 
 
Discussion 
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We presented a novel metric that summarizes the capacity of subgroup-defining 
variables towards formulating efficient treatment rules. The metric quantifies such 
capacity based on quantifying improvement in the expected efficiency of treatment 
when a covariate-informed treatment rule is used in place of a covariate-agnostic rule 
to decide which of two randomly selected subjects should receive treatment. We 
showed that the resulting index, 𝐶𝑏, is closely related to the Gini index for the 
distribution of expected treatment benefit in the population. Importantly, we showed 
that 𝐶𝑏 can also be interpreted as evaluating the benefit of covariate-informed versus 
covariate-naive treatment decisions, integrated over the range of treatment thresholds. 
Through a case study, we demonstrated how such calculations can be performed in the 
context of a trial in which the outcome was a count event. This approach can easily be 
used with a variety of inference techniques that are used in the analysis of clinical trials, 
such as logistic regression or proportional hazard and accelerated failure time models. 
For example, empirical estimates of baseline hazard and hazard ratios from a 
proportional hazards model can be used to estimate cumulative incidence of the 
outcome and the absolute rate reduction up to a time horizon of interest, which will 
provide sufficient data to calculate the related metrics.  
 
Our proposed approach is in line with recent recommendations for direct evaluation of 
treatment benefit as a function of covariates(4). A major advantage of such treatment 
benefit modeling is that covariates, and their interaction with treatment, can be 
considered jointly. In this case, the 𝐶𝑏 can be seen as a global metric of the combined 
capacity of covariates towards enabling personalized treatment decisions. A similar 
approach has recently been proposed by van Klaveren et al(28). Their proposed 'c-for-
benefit' represents the probability that from two randomly chosen pairs of individuals 
with unequal observed benefit, the pair with higher observed benefit also has a higher 
predicted benefit. In contrast, 1-𝐶𝑏 is the relative efficiency of providing treatment to 
one of two randomly selected subjects at random, as opposed to providing treatment to 
one with higher expected benefit. Comparison between the behaviors of these metrics 
remains to be evaluated in future studies.  
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The interpretation of 𝐶𝑏 as the benefit of covariate-informed treatment integrated over 
treatment thresholds allows one to devise modified versions of this index that pertain to 
a specific range on the treatment threshold. In certain instances (e.g., a positive trial 
for a treatment with low rate of adverse events), we expect that the treatment will be 
provided to the majority of the population, and covariates are to be used to find the 
minority for which treatment should be opted out. In other instances (e.g., a negative 
trial), the investigator might be in search for the minority in the population who should 
opt in for treatment. Alternatively, one can propose a minimally acceptable treatment 
benefit (or a maximally acceptable number-needed-to-treat) given the risk profile of 
treatment, which will define a boundary on the treatment threshold. The ‘partial’ 𝐶𝑏 
calculated in this way is similar in concept to the partial AUC of the ROC curve(29).  
 
The finite sample properties of the proposed index, and its sensitivity to model 
specification and various regularization techniques should be evaluated in future 
studies. Both the case study and the simulations showed that 𝐶𝑏 is sensitive to the 
choice of parametric versus semiparametric estimation, whether shrinkage estimation is 
employed, and whether estimates are corrected for optimism. Recent simulation studies 
also point towards the sensitivity of estimates of treatment effect heterogeneity to such 
specifications even in large sample sizes(30). In our simulations, parametric estimation 
with shrinkage resulted in the estimates with the lowest average root mean square 
error, but this needs to be further evaluated. In general, model specification and the 
choice of estimation method will require careful examination of model fit. When 
reporting clinical trial results, full pre-specification of the modeling approach can add to 
the credibility of estimates and consistency across studies.  
 
Other research on this topic can focus on how 𝐶𝑏 can be estimated from observational 
studies. In our case study, randomization had protected against systematic 
confounding, and the relatively large sample size protected against chance (non-
structural) imbalance of confounders. However, if this condition cannot be assured, the 
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potential outcome models must include the confounding variables. For example, if 𝐗, 
the set of covariates of interest, is a subset of a larger set 𝐗∗ that is required to block 
the confounding (backdoor) paths, then the expected treatment benefit should be 
calculated as 𝑏 = 𝐸𝐗∗{𝐸(𝑌|𝐗, 𝐴 = 0) –  𝐸(𝑌|𝐗, 𝐴 = 1)}. Evaluating this nested expectation 
remains an important topic to investigate. Another research topic is applying this 
concept to multi-arm trials. One extension of the two-subject treatment assignment 
task underlying 𝐶𝑏 to where there are m treatment options can be based on comparing 
the outcome of covariate-informed and covariate-agnostic rules when assigning each of 
m treatments to each of m randomly selected subjects.  
 
Conclusion 
Subgroup analysis in clinical trials is an early opportunity for exploring the potential of 
using patient characteristics to move from population-level treatment decisions to more 
efficient individualized treatment rules. While decision theory provides a consistent 
framework for this problem, its application requires difficult-to-establish treatment 
thresholds. Our contribution in this work was the introduction of global measures of the 
capacity of covariates in designing efficient treatment rules. To us, this is the ‘sweet 
spot’ for subgroup analysis when clinical trial results are being reported. Several 
important issues around model selection, variable election, and extension to 
observational studies and multi-arm trials remain to be explored.  
 
Acknowledgement 
The authors would like to thank Drs. Abdollah Safari and Mahyar Etminan, The 
University of British Columbia, for their insightful comments on earlier drafts. 
 
 
 
Data Sharing Statement 
 
Version 2019.08.22  
24 
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